William Z. Potter

William Z. Potter's AcademicInfluence.com Rankings

William Z. Potter

Medical

#1593

World Rank

#1949

Historical Rank

Toxicology

#16

World Rank

#18

Historical Rank

Pharmacology

#142

World Rank

#178

Historical Rank

medical Degrees

William Z. Potter

Philosophy

#4867

World Rank

#7533

Historical Rank

Logic

#2240

World Rank

#3188

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

William Z. Potter's Degrees

PhD Pharmacology University of California, San Francisco
Doctorate Medicine University of California, San Francisco

Why Is William Z. Potter Influential?

(Suggest an Edit or Addition)

(See a Problem?)

William Z. Potter's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione. (1973) (1667)
Acetaminophen-Induced Hepatic Necrosis (1974) (1479)
Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism. (1973) (1443)
Acetaminophen-induced hepatic necrosis. II. Role of covalent binding in vivo. (1973) (1152)
Bupropion: a review of its mechanism of antidepressant activity. (1995) (733)
Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. (1997) (562)
Acetaminophen‐induced hepatic injury: Protective role of glutathione in man and rationale for therapy (1974) (485)
Acetaminophen-induced hepatic necrosis. 3. Cytochrome P-450-mediated covalent binding in vitro. (1973) (480)
Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. (2004) (454)
Cerebrospinal fluid monoamine metabolites, aggression, and impulsivity in disruptive behavior disorders of children and adolescents. (1990) (401)
Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. (2008) (398)
Signal transduction pathways. Molecular targets for lithium's actions. (1995) (339)
Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. (2002) (335)
Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydrazine metabolites (1975) (293)
Acetaminophen-induced hepatic necrosis. V. Correlation of hepatic necrosis, covalent binding and glutathione depletion in hamsters. (1974) (288)
Diagnosing diagnoses. Receiver operating characteristic methods and psychiatry. (1989) (281)
Species differences in hepatic glutathione depletion, covalent binding and hepatic necrosis after acetaminophen. (1974) (280)
Assessing and interpreting treatment effects in longitudinal clinical trials with missing data (2003) (232)
The responsiveness of the Hamilton Depression Rating Scale. (2000) (229)
Interacting neurotransmitter systems. A non-experimental approach to the 5HIAA-HVA correlation in human CSF. (1986) (210)
LY354740, an mGlu2/3 Receptor Agonist as a Novel Approach to Treat Anxiety/Stress (2003) (206)
Plasma norepinephrine level in affective disorders. Relationship to melancholia. (1985) (185)
A Randomized, Placebo-Controlled, Crossover Pilot Trial of the Oral Selective NR2B Antagonist MK-0657 in Patients With Treatment-Resistant Major Depressive Disorder (2012) (177)
Antidepressants. A comparative review of the clinical pharmacology and therapeutic use of the 'newer' versus the 'older' drugs. (1989) (173)
Report of the task force on designing clinical trials in early (predementia) AD (2010) (162)
Chronic Sodium Valproate Selectively Decreases Protein Kinase C α and ε In Vitro (1994) (160)
The pharmacologic treatment of depression. (1991) (156)
Translating Glutamate: From Pathophysiology to Treatment (2011) (153)
Acetaminophen-induced hepatic necrosis. VI. Metabolic disposition of toxic and nontoxic doses of acetaminophen. (1974) (149)
Alteration of norepinephrine metabolism with desipramine and zimelidine in depressed patients. (1982) (137)
Dual Monoamine Modulation for Improved Treatment of Major Depressive Disorder (2003) (136)
Cerebrospinal fluid neurochemistry in children and adolescents with obsessive-compulsive disorder. (1992) (132)
Selective antidepressants and cerebrospinal fluid. Lack of specificity on norepinephrine and serotonin metabolites. (1985) (124)
Cerebrospinal Fluid Homovanillic Acid Predicts Behavioral Response to Stimulants in 45 Boys with Attention Deficit/Hyperactivity Disorder (1996) (124)
Bupropion in depression. II. The role of metabolites in clinical outcome. (1988) (114)
Idazoxan and Response to Typical Neuroleptics in Treatment-Resistant Schizophrenia (1996) (110)
Metabolism of Tricyclic Antidepressants (1999) (109)
Comparative Tolerability Profiles of the Newer versus Older Antidepressants (1994) (103)
Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF (2015) (102)
Duloxetine Increases Serotonin and Norepinephrine Availability in Healthy Subjects: A Double-Blind, Controlled Study (2003) (99)
Modulation of Protein Kinase C Isozymes and Substrates by Lithium: The Role of Myo-inositol (1996) (99)
Exaggerated orthostatic responsivity of plasma norepinephrine in depression. (1985) (99)
Hepatic necrosis caused by furosemide (1974) (98)
A randomized proof-of-mechanism trial applying the ‘fast-fail’ approach to evaluating κ-opioid antagonism as a treatment for anhedonia (2020) (96)
Treatment of childhood hyperactivity with desipramine: Plasma drug concentration, cardiovascular effects, plasma and urinary catecholamine levels, and clinical response (1986) (96)
Clinical Assessment of Norepinephrine Transporter Blockade Through Biochemical and Pharmacological Profiles (2004) (95)
Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia. (1990) (94)
The mechanisms of action of lithium. II. Effects on adenylate cyclase activity and beta-adrenergic receptor binding in normal subjects. (1991) (93)
Guanine nucleotide-binding proteins in bipolar affective disorder. Effects of long-term lithium treatment. (1995) (91)
Active metabolites of imipramine and desipramine in man (1982) (90)
Fenfluramine and dextroamphetamine treatment of childhood hyperactivity. Clinical and biochemical findings. (1989) (89)
Hydroxylated metabolites of tricyclic antidepressants: preclinical assessment of activity. (1979) (89)
Stimulant drug treatment of hyperactivity: Biochemical correlates (1990) (87)
Antidepressants reduce whole-body norepinephrine turnover while enhancing 6-hydroxymelatonin output. (1988) (87)
Urinary 3-methoxy-4-hydroxyphenylglycol and major affective disorders. A replication and new findings. (1984) (86)
A neuroanatomical and biochemical basis for attention deficit disorder with hyperactivity in children: a defect in tonic adrenaline mediated inhibition of locus coeruleus stimulation. (1989) (85)
Circadian covariation of norepinephrine and serotonin in the locus coeruleus and dorsal raphe nucleus in the rat (1986) (83)
Changes in cerebrospinal fluid neurochemistry during treatment of obsessive-compulsive disorder with clomipramine. (1994) (82)
Desipramine pharmacokinetics in Chinese and Caucasian volunteers. (1984) (82)
Increase in AP-1 Transcription Factor DNA Binding Activity by Valproic Acid (1997) (81)
Attenuation of Cyclic AMP Production by Carbamazepine (1996) (80)
The history and current state of antidepressant clinical trial design: a call to action for proof-of-concept studies. (2008) (80)
Bupropion in depression. I. Biochemical effects and clinical response. (1988) (79)
In Vivo Evidence that Lithium Inactivates Gi Modulation of Adenylate Cyclase in Brain (1992) (78)
Chronic sodium valproate selectively decreases protein kinase C alpha and epsilon in vitro. (1994) (78)
Imipramine and desipramine in plasma and spinal fluid: relationship to clinical response and serotonin metabolism. (1978) (78)
Metabolic activation of furosemide to a chemically reactive, hepatotoxic metabolite. (1976) (77)
Catecholamines in depression: an update. (1994) (76)
The mechanisms of action of lithium. I. Effects on serotoninergic and noradrenergic systems in normal subjects. (1991) (75)
The problem of measurement error in multisite clinical trials. (1998) (75)
Clozapine in China: a review and preview of US/PRC collaboration (2004) (74)
Utility of Imaging-Based Biomarkers for Glutamate-Targeted Drug Development in Psychotic Disorders: A Randomized Clinical Trial (2018) (74)
Psychoses associated with bupropion treatment. (1985) (73)
Lysergic acid diethylamide (LSD) administration selectively downregulates serotonin2 receptors in rat brain. (1990) (72)
Regulation of signal transduction pathways by mood-stabilizing agents: implications for the delayed onset of therapeutic efficacy. (1996) (72)
Single-dose kinetics predict steady-state concentrations on imipramine and desipramine. (1980) (70)
The Effects of ECT on Brain Glucose: A Pilot FDG PET Study (1999) (69)
NIMH workshop report on treatment of bipolar disorder. (1990) (67)
The effects of intravenous clomipramine on neurohormones in normal subjects. (1989) (67)
Use of ECT with treatment-resistant depressed patients at the National Institute of Mental Health. (1981) (67)
Clorgyline. A new treatment for patients with refractory rapid-cycling disorder. (1982) (66)
The Double-Blind Variable Placebo Lead-in Period: Results From Two Antidepressant Clinical Trials (2001) (65)
Effect of low-dose clorgyline on 24-hour urinary monoamine excretion in patients with rapidly cycling bipolar affective disorder. (1982) (61)
Idazoxan: a selective alpha 2-antagonist and effective sustained antidepressant in two bipolar depressed patients. (1989) (61)
Medicines for the Mind: Policy-Based “Pull” Incentives for Creating Breakthrough CNS Drugs (2014) (61)
Catecholamines in depression: a cumulative study of urinary norepinephrine and its major metabolites in unipolar and bipolar depressed patients versus healthy volunteers at the NIMH (1999) (61)
The Impact of Restrictive Entry Criterion During the Placebo Lead‐in Period (2000) (60)
Effects of desmethylimipramine on plasma norepinephrine, pulse, and blood pressure (1983) (58)
High Levels of Gsα in Platelets of Euthymic Patients With Bipolar Affective Disorder (1997) (56)
Monoamine neurotransmitter interactions and the prediction of antidepressant response. (1987) (53)
A double-blind study comparing idazoxan and bupropion in bipolar depressed patients. (1999) (52)
Monoamine neurotransmitter interactions in drug-free and neuroleptic-treated schizophrenics. (1993) (52)
Imaging cAMP-specific phosphodiesterase-4 in human brain with R-[11C]rolipram and positron emission tomography (2002) (52)
Abnormal neuroendocrine responsivity to acute I.V. clomipramine challenge in depressed patients (1990) (51)
The Role of Metabolites of Antidepressants in the Treatment of Depression (1997) (50)
Treatment of hyperactive children with monoamine oxidase inhibitors. II. Plasma and urinary monoamine findings after treatment. (1985) (48)
Lithium administration modulates platelet Gi in humans. (1992) (47)
Idazoxan, an ??2 Antagonist, Augments Fluphenazine in: Schizophrenic Patients (1993) (47)
Gender differences in pharmacokinetics and pharmacodynamics of psychotropics: focus on women. (1991) (46)
Concentration gradient of CSF monoamine metabolites in children and adolescents (1988) (46)
Electroconvulsive therapy--a modern medical procedure. (1993) (46)
Biochemical changes after hepatic injury from toxic doses of acetaminophen or furosemide. (1976) (46)
Specific norepinephrine and serotonin uptake inhibitors in man: A crossover study with pharmacokinetic, biochemical, neuroendocrine and behavioral parameters (1981) (46)
Toxic Drug Reactions (1975) (45)
Fluctuating high urinary phenylethylamine excretion rates in some bipolar affective disorder patients (1982) (45)
Effects of Valproic Acid on β-adrenergic Receptors, G-proteins, and Adenylyl Cyclase in Rat C6 Glioma Cells (1996) (45)
The effects of antidepressants on the cerebrospinal fluid homovanillic acid/5‐hydroxyindoleacetic acid ratio (1987) (44)
Lithium effects on noradrenergic-linked adenylate cyclase activity in intact rat brain: an in vivo microdialysis study (1991) (44)
Effects of electroconvulsive treatment on somatostattn, neuropeptide Y, endothelin, and neurokinin a concentrations in cerebrospinal fluid of depressed patients: A pilot study (1995) (43)
NOREPINEPHRINE METABOLITE STUDIES IN AFFECTIVE ILLNESS (1979) (43)
Discovering translational biomarkers in neurodevelopmental disorders (2018) (42)
Adrenoceptors and serotonin receptor function: relevance to antidepressant mechanisms of action. (1996) (42)
Effects of antidepressant treatments on dopamine turnover in depressed patients. (1983) (42)
Decision-making using fMRI in clinical drug development: revisiting NK-1 receptor antagonists for pain. (2012) (41)
Evaluation of zimeldine in Alzheimer's disease. Cognitive and biochemical measures. (1985) (41)
High correlation of norepinephrine and its major metabolite excretion rates. (1982) (40)
Altered hydroxydesipramine concentrations in elderly depressed patients (1982) (39)
Biochemical changes after hepatic injury by allyl alcohol and N-hydroxy-2-acetylaminofluorene. (1976) (39)
Electroconvulsive treatment and lithium carbonate. Their effects on norepinephrine metabolism in patients with primary, major depressions. (1983) (38)
Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS) (2020) (38)
Plasma norepinephrine in chronic schizophrenia. (1990) (38)
High reverse T3 levels in manic and unipolar depressed women (1982) (38)
The first implementation of the NIMH FAST-FAIL approach to psychiatric drug development (2018) (37)
Clinical studies on norepinephrine metabolism: How to interpret the numbers (1986) (37)
8 – Sources of Variance in Clinical Studies of MHPG (1983) (37)
Second-generation antidepressants. (1984) (36)
Rating the Raters: Assessing the Quality of Hamilton Rating Scale for Depression Clinical Interviews in Two Industry-sponsored Clinical Drug Trials (2006) (36)
Neurophysiologic Correlates of Side Effects in Normal Subjects Randomized to Venlafaxine or Placebo (2005) (34)
Signal transduction modulation by lithium: cell culture, cerebral microdialysis and human studies. (1991) (34)
Chronic Li+ attenuates agonist- and phorbol ester-mediated Na+/H+ antiporter activity in HL-60 cells. (1990) (34)
Conceptual, Regulatory and Strategic Imperatives in the Early Days of EEG-Based Biomarker Validation for Neurodevelopmental Disabilities (2019) (33)
Bipolar depression: specific treatments. (1998) (32)
Gender Differences in Brain Metabolic and Plasma Catecholamine Responses to Alpha2-Adrenoceptor Blockade (1997) (30)
Plasma steady‐state concentrations of hydroxylated metabolites of clomipramine (1982) (30)
Concentrations of desipramine in elderly women. (1981) (30)
Plasma haloperidol levels and clinical response in acute schizophrenia. (1982) (30)
B : ALGORITHMS FOR THE TREATMENT OF BIPOLAR, MANIC-DEPRESSIVE ILLNESS (1995) (30)
Reduction of norepinephrine turnover by serotonergic drug in man. (1984) (30)
Hypothalamic-pituitary-adrenal axis and monoamine transmitter activity in depression: A pilot study of central and peripheral effects of electroconvulsive therapy (1991) (29)
Cerebral glucose metabolism during pharmacologic studies: test-retest under placebo conditions. (1996) (29)
Characterization of β 1- and β 2-adrenoceptor subtypes in the rat sinoatrial node and stellate ganglia by quantitative autoradiography (1989) (28)
Changes in Brain Function during Administration of Venlafaxine or Placebo to Normal Subjects (2008) (28)
Active metabolites of antidepressants: pharmacodynamics and relevant pharmacokinetics. (1984) (28)
Effects of renal clearance on plasma concentrations of homovanillic acid. Methodologic cautions. (1989) (27)
Possible mechanism of isoniazid related hepatic injury (1974) (27)
Treatment of bipolar depressive mood disorders: Algorithms for pharmacotherapy. (1997) (27)
Reliability of urinary monoamine and metabolite output measurements in depressed patients. (1983) (27)
Dopamine D1 receptor in rat brain: a quantitative autoradiographic study with125I-SCH 23982 (1987) (27)
Characterization of beta 1- and beta 2-adrenoceptor subtypes in the rat atrioventricular node by quantitative autoradiography. (1988) (27)
Is bigger better for depression trials? (2008) (26)
Hormonal responses to zimelidine and desipramine in depressed patients (1984) (25)
Behavioral and endocrine responses to clomipramine in panic disorder patients with or without alcoholism (1995) (25)
Axonal transport of dopamine D1 receptors in the rat brain (1987) (25)
Acute cardiovascular effects of tranylcypromine: correlation with plasma drug, metabolite, norepinephrine, and MHPG levels. (1991) (24)
Five antidepressant treatments in depressed patients. Effects on urinary serotonin and 5-hydroxyindoleacetic acid output. (1984) (24)
Tricyclic antidepressants do not alter thyroid hormone levels in patients suffering from a major affective disorder (1981) (24)
A multicenter study of ketamine effects on functional connectivity: Large scale network relationships, hubs and symptom mechanisms (2019) (23)
High levels of Gs alpha in platelets of euthymic patients with bipolar affective disorder. (1997) (23)
The effect of desmethylimipramine on the metabolism of norepinephrine. (1984) (23)
Biomarkers in psychotropic drug development: integration of data across multiple domains. (2005) (23)
Effects of amitriptyline, desipramine and zimeldine, alone and in combination with ethanol, on information processing and memory in healthy volunteers (1983) (23)
Drug metabolism in the production of liver injury. (1975) (22)
Imaging as a biomarker in drug discovery for Alzheimer’s disease: is MRI a suitable technology? (2014) (22)
Noradrenergic Function in Depressive Disorders (1993) (21)
Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglumetad and TS-134 on ketamine-induced psychotic symptoms and pharmacoBOLD in healthy volunteers (2020) (21)
Idazoxan, an alpha 2 antagonist, augments fluphenazine in schizophrenic patients: a pilot study. (1993) (21)
Down-regulation of PKC alpha by lithium in vitro. (1995) (20)
Antidepressants, Metabolites, and Apparent Drug Resistance (1990) (20)
Rapid mood cycles after a noradrenergic but not a serotonergic antidepressant. (1979) (20)
High correlations of norepinephrine, dopamine, and epinephrine and their major metabolite excretion rates. (1988) (19)
Intravenous alprazolam challenge in normal subjects (1989) (19)
Chronic electroconvulsive shock increases D-1 receptor binding in rat substantia nigra. (1989) (19)
Algorithms for the treatment of bipolar manic-depressive illness. (1995) (18)
Alterations in Cyclic AMP Generation and G Protein Subunits following Transient Ischemia in Gerbil Hippocampus (1995) (17)
Methodological issues in the measurement of urinary MHPG (1981) (17)
Lack of seasonal variation in pediatric lumbar cerebrospinal fluid neurotransmitter metabolite concentrations (1989) (17)
Dissociation of norepinephrine turnover from alpha‐2 responses after clorgiline (1988) (16)
Familial hypokalemia associated with renal interstitial fibrosis. (1974) (16)
High positive correlation between urinary free tyramine excretion rate and "whole body" norepinephrine turnover in depressed patients. (1982) (16)
PROOF OF CONCEPT: FUNCTIONAL MODELS FOR DRUG DEVELOPMENT IN HUMANS (2002) (16)
Effects of S-adenosyl-methionine on plasma norepinephrine, blood pressure, and heart rate in healthy volunteers (1986) (15)
Neurochemical and neuroendocrine dysregulation in affective disorders. (1986) (15)
Common mechanism of action of biochemically “specific” antidepressants (1984) (15)
Identifying pharmacodynamic protein markers of centrally active drugs in humans: a pilot study in a novel clinical model. (2007) (15)
The Tyramine Pressor Test May Have Limited Sensitivity, Especially in the Presence of Dual Serotonin/Norepinephrine Uptake Inhibition★ (2002) (15)
Differences in lithium effects in depressed and healthy subjects (1985) (15)
Lymphocyte beta adrenergic receptor function versus catecholamines in depression (1988) (14)
The Biology of Affective Illness: Amine Neurotransmitters and Drug Response (1978) (14)
Derisking Psychiatric Drug Development: The NIMH's Fast Fail Program, A Novel Precompetitive Model. (2016) (14)
Possible Role of Hydrazine Group in Hypoglycemia Associated with the Use of Certain Monoamine-oxidase Inhibitors (MAOI's) (1969) (14)
Responses to α 2-adrenoceptor blockade by idazoxan in healthy male and female volunteers (1997) (14)
Down-regulation of beta receptors by desipramine in vitro involves PKC/phospholipase A2. (1991) (13)
International Psychopharmacology Algorithm Project Report. (1995) (13)
Are monoamine metabolites in cerebrospinal fluid worth measuring? (1993) (13)
Clinical investigation of monoamine neurotransmitter interactions (2005) (13)
Mechanisms of action of antipanic drugs (1990) (13)
Public–private partnerships to revitalize psychiatric drug discovery (2014) (13)
G-Protein Level Quantification in Platelets and Leukocytes from Patients with Panic Disorder (1996) (13)
A survey of psychotropic medications not available in the United States. (1991) (13)
Effect of IL-1α on the release of norepinephrine in rat hypothalamus (1998) (13)
Effects of chronic lithium treatment on platelet PKC isozymes in Alzheimer's and elderly control subjects (1993) (13)
Combined Lithium and Electroconvulsive Therapy: Pharmacokinetic and Pharmacodynamic Interactions. (1987) (12)
Pharmacologic profile of natural products used to treat psychotic illnesses. (1995) (12)
ECT alters human monoamines in a different manner from that of antidepressant drugs. (1988) (12)
Redirecting the revolution: new developments in drug development for psychiatry (2019) (12)
Nortriptyline formation after single oral and intramuscular doses of amitriptyline (1982) (12)
Guanine nucleotide binding proteins in opioid-dependent patients (1997) (12)
Platelet α2-adrenoreceptors in depression: a critical examination (1993) (12)
A pharmacodynamic study of the α2‐adrenergic receptor antagonist ethoxyidazoxan in healthy volunteers (1994) (12)
Temporal association between depression-dependent dyskinesias and high urinary phenylethylamine output. (1983) (12)
Lymphocyte β-Adrenergic Receptor Modification in Bulimia (1988) (12)
Diurnal variation in the concentrations of catecholamines and indoleamines in the median eminence and in the intermediate and posterior lobes of the pituitary gland of the male rat (1989) (12)
Cerebrospinal fluid monoamine metabolites in childhood-onset schizophrenia. (1997) (11)
CSF, plasma, and urine: what do concomitant measurements of norepinephrine and its metabolites mean? (1985) (11)
Optimizing early Go/No Go decisions in CNS drug development (2015) (11)
Clinical response to clozapine in patients with schizophrenia. (1994) (11)
Chronic exposure of C6 glioma cells to desipramine desensitizes beta-adrenoceptors, but increases KL/KH ratio. (1991) (11)
Bupropion, ECT, and dopaminergic overdrive. (1991) (11)
Effects of chronic desipramine on plasma norepinephrine concentrations and cardiovascular parameters in elderly depressed women: a preliminary report. (1984) (11)
Regional brain glucose metabolism after acute α2‐blockade by idazoxan (1995) (10)
In Vivo Evidence that Nonneuronal β‐Adrenoceptors as Well as Dopamine Receptors Contribute to Cyclic AMP Efflux in Rat Striatum (1994) (10)
Quantitative autoradiography of beta-adrenoceptors in the cardiac vagus ganglia of the rat. (1988) (10)
Psychotropic medications and work performance. (1990) (10)
The Relationship between Brain Receptor Occupancy and Alerting Effects in Humans Support MK-0249 and MK-3134 As Inverse Agonists at the Histamine Subtype-3 Pre-synaptic Receptor (2009) (10)
Benefits Exceed Risks of Newer Antidepressant Medications in Youth—Maybe Not (2009) (9)
Dose-dependent effects of intravenous alprazolam on neuroendocrine, biochemical, cardiovascular, and behavioral parameters in humans (2005) (9)
Noradrenergic Function in Affective Illness (1979) (9)
Disparate serum thioridazine concentrations: liquid chromatography versus radioreceptor assay. (2009) (9)
Binding of imipramine to plasma protein and to brain tissue: Relationship to CSF tricyclic levels in man (1979) (9)
Interethnic dissociation between debrisoquine and desipramine hydroxylation. (1985) (9)
Methodological considerations for the development of new treatments for bipolar disorder. (1999) (9)
Pharmacological issues in the treatment of bipolar disorder: focus on mood-stabilizing compounds. (1993) (9)
Ten day administration of desipramine produces an increase in KL/KH for beta-receptors in rat hippocampus. (1989) (9)
Biochemical classifications of diagnostic subgroups and D-type scores. (1989) (9)
Biomarkers in psychotropic drug development. (2002) (9)
Tissue localization of 7- and 8-hydroxychlorpromazines. (1974) (8)
Zimelidine and norzimelidine protein binding measured by equilibrium dialysis and cerebrospinal fluid (1982) (8)
Active metabolites of tricyclic antidepressants (1981) (8)
Comparative pharmacokinetics of zimelidine and desipramine in man following acute and chronic administration (1979) (8)
Disparate Biochemical Actions of Electroconvulsive Therapy and Antidepressant Drugs. (1988) (8)
Controlling Placebo Response in Drug Development: Lessons Learned from Psychopharmacology (2014) (8)
The NIMH ‘Fast-Fail Trials’ (FAST) Initiative: Rationale, Promise, and Progress (2020) (8)
New Era for Novel CNS Drug Development (2012) (8)
Crossover study of zimelidine and desipramine in depression: evidence for amine specificity [proceedings]. (1981) (8)
Oral administration of heptylphysostigmine in healthy volunteers: a preliminary study. (1994) (8)
Accidental antidepressants: search for specific action. (1987) (7)
BIOMARKERS AND NEUROBEHAVIORAL DIAGNOSIS. (2021) (7)
Characterization of beta 1- and beta 2-adrenoceptor subtypes in the rat sinoatrial node and stellate ganglia by quantitative autoradiography. (1989) (7)
Chronic alpha-2 antagonism increases norepinephrine, blocks GH release, and is antidepressant (1989) (7)
Effects of chronic exposure to ethanol alone and in combination with desipramine on beta-adrenoceptors of rat brain. (1990) (7)
Idazoxan down-regulates β-adrenoceptors on C6 glioma cells in vitro (1992) (6)
MONOAMINERGIC ACTIONS OF ECT (1992) (6)
Axonal transport of angiotensin-converting enzyme in the rat striatonigral pathway (1988) (6)
Acute alpha 2 blockade by idazoxan increases insulin and lowers plasma glucose during positron emission tomography. (1997) (6)
Effects of psychotropic drugs on neurotransmitters in man. (1987) (6)
Norepinephrine in the Affective Disorders: Receptor Assessment Strategies (1985) (6)
Amelioration of Psychosis with Carbidopa: A Case Report (1984) (6)
Effect of IL-1alpha on the release of norepinephrine in rat hypothalamus. (1998) (6)
Metabolism of tri cyclic anti depressants in human liver microsomes (1981) (6)
Dosage regimen design for cyclic antidepressants: a review of pharmacokinetic methods. (1991) (5)
Dopamine D1 receptor in rat brain: a quantitative autoradiographic study with 125I-SCH 23982. (1987) (5)
Biological Theories of Depression and Implications for Current and New Treatments (2011) (5)
Characterization of / 3 jand / 32-Adrenoceptor Subtypes in the Rat Atrioventricular Node by Quantitative Autoradiography (2005) (5)
Dose ranging for trials through biomarkers of drug effects (2010) (5)
Psychotherapeutic drugs and biogenic amines. Current concepts and therapeutic implications. (1984) (4)
Responses to alpha 2-adrenoceptor blockade by idazoxan in healthy male and female volunteers. (1997) (4)
Clinical Efficacy and Target Engagement of Glutamatergic Drugs: Placebo-Controlled RCTs of Pomaglumetad and TS-134 for Reversal of Ketamine-Induced Psychotic Symptoms and PharmacoBOLD in Healthy Volunteers (2020) (4)
Biochemical effects of selective serotonin-reuptake inhibitors in man (1988) (4)
Acute noradrenergic effects of desipramine in depression. (1991) (4)
Regional brain glucose metabolism after acute alpha 2-blockade by idazoxan. (1995) (4)
Pharmacokinetic and dynamic correlates of intravenous alprazolam challenge (1991) (4)
Chronic Lithium Administration Enhances Noradrenergic Responses to Intravenous Administration of the α2 Antagonist Idazoxan in Healthy Volunteers (2004) (4)
Cerebral glucose metabolic and plasma catecholamine responses to the α2 adrenoceptor antagonist ethoxyidazoxan given to healthy volunteers (1999) (4)
Introduction: Norepinephrine as an ‘umbrella’ neuromodulators (1986) (4)
Norepinephrine in the Affective Disorders: Classic Biochemical Approaches (1985) (4)
Mining the secrets of the CSF: developing biomarkers of neurodegeneration. (2012) (4)
ECT and delirium in Parkinson's disease. (1992) (4)
Neurotransmitter interactions as a target of drug action. (1989) (3)
Lymphocyte beta-adrenergic receptor modification in bulimia. (1988) (3)
Treatment of major depression: selection of initial drug. (1997) (3)
The effect of clorgyline on noradrenergic function (2004) (3)
The study of possible influences of licit and illicit drugs on driver behavior (1971) (2)
Hydroxy metabolite concentrations: role of renal clearance (1983) (2)
Translational and Early Phase Strategies for Treatment Development: Report of ISCTM Autumn 2013 Symposium. (2015) (2)
Current drug development for antidepressants and ideas addressing downstream glutamate: the ketamine example (2014) (2)
Novel prodrug PRX-P4-003, selectively activated by gut enzymes, may reduce the risk of iatrogenic addiction and abuse. (2018) (2)
Central Nervous System Trial Failures: Using the Fragile X Syndrome-mGluR5 Drug Target to Highlight the Complexities of Translating Preclinical Discoveries Into Human Trials. (2022) (2)
Effects of chronic lithium treatment on signal transduction mechanisms in HL60 cells (1989) (2)
ECT treatment does not enhance neuroendocrine responses to serotonergic challenge (1992) (2)
The 5-HT1A Receptor: an unkept promise? (2000) (2)
Combined fluoxetine and tricyclic antidepressants. (1989) (2)
ECT methodologic issues. (1994) (2)
Prediction of steady state plasma concentration of imipramine [proceedings]. (1978) (2)
EFFECTS OF LITHIUM ON SIGNAL TRANSDUCTION IN HUMANS (1992) (2)
A Reply to El-Mallakh. (1987) (2)
Controlling the placebo response rates in depression (1998) (2)
Alprazolam and aggression. (1989) (2)
Comments on gender differences in pharmacokinetics and pharmacodynamics. (1993) (2)
Promising medications not available in the United States (1994) (1)
Dr. Golden and Associates Reply (2006) (1)
Lithium and ECT Interaction. (1987) (1)
Translating Glutamate : From Pathophysiology to Treatment Citation Javitt (2012) (1)
Augmentation of neuroleptics with idazoxan: Focus on noradrenergic function in schizophrenia (1993) (1)
S.08.01 The metabotropic glutamate receptor progress towards novel therapeutics (2003) (1)
Carbamazepine increased pregnenolone synthesis blocked by peripheral type benzodiazepine receptor antagonist (1995) (1)
Controlling Placebo Response in Drug Development: Lessons Learned from Psychopharmacology (2014) (1)
Advances in Treatment and Perspectives for New Interventions in Mood and Anxiety Disorders (2003) (1)
Key issues in the diagnosis and treatment of bipolar disorders. (1996) (1)
Panic provocation studies with placebo (2000) (1)
Valproate and mood disorders: perspectives. Introduction. (1992) (1)
Psychotherapeutic Drugs and Biogenic Amines (1984) (1)
S-25-5 Clinical onset of antidepressant action: Implications for new drug development (1996) (1)
Duloxetine: Pharmacodynamic evidence of dual reuptake inhibition in healthy subjects (2002) (0)
BUPROPION, ECT, AND DOPAMINERGIC OVERDRIVE. REPLY (1991) (0)
Effects of desmethylimipramine on plasma norepinephrine pulse and blood pressure (1983) (0)
Plasma antidepressant level changes: kinetics versus methods. (1986) (0)
A Reply to Pearlman. (1988) (0)
Effects of chronic lithium administration on the beta-adrenoceptors in rat frontal cortex and striatum (1989) (0)
Side Effect Profile and Safety of Antidepressants in Light of New Therapeutic Indications (1997) (0)
E.05.02 Making better early go/no-go decisions in drug development progress in the NIMH FAST-FAIL programme (2014) (0)
Effects of antidepressant treatments on ‘whole body’ norepinephrine turnover (1983) (0)
The Paired FDG Pet Scan Method: Validation Using Placebo Infusions (1994) (0)
Clinical "Response" to "Convulsive" Therapy. (1985) (0)
COMBINED MEASURES OF NORADRENERGIC OUTPUT AND RECEPTOR RESPONSIVITY IN DEPRESSION (1992) (0)
28-3 Future antidepressants: What is possible? (1997) (0)
Reply to Comments by Dr. Balon (2007) (0)
Correction to: Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS) (2021) (0)
Effects of drug washout on CSF monoamine and psychoendocrine variables. (1986) (0)
Phenylethylamine and tyramine outputs in patients with affective disorders: behavioral and biochemical correlates. (1984) (0)
NORADRENERGIC AND CARDIOVASCULAR EFFECTS OF CHRONIC S-ADENYOSYL-METHIONINE IN HEALTHY VOLUNTEERS (1986) (0)
Norepinephrine as an 'umbrella' neuromodulator. (1986) (0)
STEADY‐STATE PREDICTIONS BASED ON FIRST DOSE DATA (1992) (0)
324. Implications of a significant treatment by country interaction (1998) (0)
82-3 Hormones and antidepressants: implications for new drug development (1997) (0)
A randomized proof-of-mechanism trial applying the ‘fast-fail’ approach to evaluating κ-opioid antagonism as a treatment for anhedonia (2020) (0)
Augmentation of Response to Typical Neuroleptic Treatment Using Idazoxan, an Alpha-2 Antagonist, in Patients with Schizophrenia (1994) (0)
Validation of a suite of ERP and QEEG biomarkers in a pre-competitive, industry-led study in subjects with schizophrenia and healthy volunteers (2023) (0)
119. Translating Neuroscience Into Drug Development: Evolving NIMH Strategy (2019) (0)
Effects of typical and atypical neuroleptics on plasma and urinary monoamine metabolites (1989) (0)
Methods to facilitate early exploratory testing of novel psychopharmacologic agents in humans. (1993) (0)
Clinical Pharmacokinetics of Antidepressants (1984) (0)
New Clinical Drug Evaluation Unit (NCDEU) annual meeting: a great opportunity for early career psychiatrists. (2012) (0)
S-3-4 Depression and somatization: A neurochemical link? (1996) (0)
Commentary on the management of treatment-resistant affective disorder: clinical perspectives (1992) (0)
Major depression: The validity of a diagnosis (1993) (0)
Better Approaches to Derisking Psychiatric Drug Development are Needed, Not New Funding Mechanisms (2022) (0)
274. Early clinical development of psychoactive drugs: Pro's and con's of academic collaborations (1998) (0)
CSF 5-HIAA, personality, aggression, and social competence in childhood and adolescence (1989) (0)
Two novel tools for evaluating GlyT1, a potential target for the treatment of shizophrenia (2008) (0)
Advances in psychopharmacology: Predicting and improving treatment response CRC Press, Boca Raton, Florida (1984). 327 pp. $90. (U.S.A.); $103 (Foreign) Edited by Mark S. Gold, R. Bruce Lydiard, and John S. Carman (1985) (0)
Introduction (1992) (0)
Pharmacogenetics of Psychotropic Drugs: Pharmacogenetics in psychotropic drug discovery and development (2002) (0)
HYDROXYLATED METABOLITES OF TRICYCLIC ANTIDEPRESSANTS: INHIBITION OF AMINE UPTAKE AND OTHER PRE-CLINICAL STUDIES (1979) (0)
CSF homovanillic acid predicts behavioral response to stimulants in 47 ADHD boys (1995) (0)
The Tricyclic Antidepressants (1986) (0)
Different Doses of Neuroleptics for Genetically Different Groups (1984) (0)
Idazoxan down-regulates beta-adrenoceptors on C6 glioma cells in vitro. (1992) (0)
Psychotherapeutic Medications Development Program (PMDP). (1993) (0)
In Memoriam Donald S. Robinson, MD (2022) (0)
Discovering translational biomarkers in neurodevelopmental disorders (2018) (0)
Evidence for rating distortion during study lead-in periods: Implications for study design and outcome (1998) (0)
Proteomic Biomarkers for Brain Disorders: Technical Considerations and Challenges (2014) (0)
P-18-16 Increased levels of Gαs in platelets of euthymic bipolar affective disorder patients (1996) (0)
Drug Discovery and Development New Era for Novel CNS Drug Development (2012) (0)
Refractory Depression: Is There a Next Step? (1994) (0)
116. Results of the NIMH FAST-MAS Phase IIa Proof of Mechanism Study of the Effects of the Selective κ Opioid Antagonist JNJ-67953964 on fMRI Ventral Striatal Activity in Anhedonic Patients (2019) (0)
Real changes can enhance information yield on novel psychopharmacologic agents (2023) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With William Z. Potter?

William Z. Potter is affiliated with the following schools:

William Z. Potter's Academic­Influence.com Rankings

William Z. Potter's Degrees

Why Is William Z. Potter Influential?

William Z. Potter's Published Works

Published Works

What Schools Are Affiliated With William Z. Potter?

William Z. Potter's AcademicInfluence.com Rankings